Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048008 · ClinicalTrials.gov registry record · Phase 1
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
A Phase 1 study, sponsored by DEKK-TEC.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01048008 is a Phase 1 study that has completed, run by DEKK-TEC. The registered enrollment target is 22 participants.
The verdict
NCT01048008, a Phase 1 study, has completed, sponsored by DEKK-TEC.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and dog models; and no behavioral cognitive impairment/neurotoxicities were noted in mouse and rat models. The drug is ready for human use as an soy bean oil/lecithin/glycerin water emulsion, the latter which has been documented - chemically and biologically to be stable and safe. Patients are currently being enrolled and treated with the protocol. Patients with advanced cancer, with or without central nervous system involvement will be eligible for enrollment, providing the required blood and other eligibility requirements are met.
Interventions
- DRUG DM-CHOC-PEN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048008
The ClinicalTrials.gov registry entry for NCT01048008 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DEKK-TEC, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DM-CHOC-PEN is the first listed.
NCT01048008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048008 about?
NCT01048008 is a clinical study titled "Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer". DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and dog models; and no behavioral cognitive impairment/neurotoxicities were...
What is the current status of trial NCT01048008?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01048008?
The interventions under investigation include: DM-CHOC-PEN (DRUG).
Who is sponsoring clinical trial NCT01048008?
This trial is sponsored by DEKK-TEC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.